期刊文献+

Mesenchymal stem cells: A new diagnostic tool?

Mesenchymal stem cells: A new diagnostic tool?
下载PDF
导出
摘要 Mesenchymal stem cells(MSCs) are progenitor cells capable of self-renewal that can differentiate in multiple tissues and, under specific and standardizedculture conditions, expand in vitro with little phenotypic alterations. In recent years, preclinical and clinical studies have focused on MSC analysis and understanding the potential use of these cells as a therapy in a wide range of pathologies, and many applications have been tested. Clinical trials using MSCs have been performed(e.g., for cardiac events, stroke, multiple sclerosis, blood diseases, auto-immune disorders, ischemia, and articular cartilage and bone pathologies), and for many genetic diseases, these cells are considered an important resource. Considering of the biology of MSCs, these cells may also be useful tools for understanding the physiopathology of different diseases, and they can be used to develop specific biomarkers for a broad range of diseases. In this editorial, we discuss the literature related to the use of MSCs for diagnostic applications and we suggest new technologies to improve their employment. Mesenchymal stem cells (MSCs) are progenitor cellscapable of self-renewal that can differentiate inmultiple tissues and, under specific and standardized culture conditions, expand in vitro with little phenotypicalterations. In recent years, preclinical andclinical studies have focused on MSC analysis andunderstanding the potential use of these cells as atherapy in a wide range of pathologies, and manyapplications have been tested. Clinical trials usingMSCs have been performed (e.g. , for cardiac events,stroke, multiple sclerosis, blood diseases, auto-immunedisorders, ischemia, and articular cartilage and bonepathologies), and for many genetic diseases, thesecells are considered an important resource. Consideringof the biology of MSCs, these cells may also be usefultools for understanding the physiopathology of differentdiseases, and they can be used to develop specificbiomarkers for a broad range of diseases. In thiseditorial, we discuss the literature related to the use ofMSCs for diagnostic applications and we suggest newtechnologies to improve their employment.
出处 《World Journal of Stem Cells》 SCIE CAS 2015年第5期789-792,共4页 世界干细胞杂志(英文版)(电子版)
关键词 MESENCHYMAL STEM CELLS Biomarkers NEXT generation SEQUENCING DIAGNOSTIC tool Tumorinitiatingcells Mesenchymal stem cells Biomarkers Next generation sequencing Diagnostic tool Tumor-initiating cells
  • 相关文献

参考文献30

  • 1Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. Howmesenchymal stem cells interact with tissue immune responses.Trends Immunol 2012; 33: 136-143 [PMID: 22227317 DOI:10.1016/j.it.2011.11.004].
  • 2Jang JE, Hyun SY, Kim YD, Yoon SH, Hwang DY, Kim SJ, KimY, Kim JS, Cheong JW, Min YH. Risk factors for progression fromcytomegalovirus viremia to cytomegalovirus disease after allogeneichematopoietic stem cell transplantation. Biol Blood MarrowTransplant 2012; 18: 881-886 [PMID: 22062802].
  • 3Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V,Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, UccelliA. Human mesenchymal stem cells modulate B-cell functions.Blood 2006; 107: 367-372 [PMID: 16141348 DOI: 10.1182/blood-2005-07-2657].
  • 4Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, MingariMC, Moretta L. Mesenchymal stem cells inhibit natural killercellproliferation, cytotoxicity, and cytokine production: role ofindoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111:1327-1333 [PMID: 17951526 DOI: 10.1182/blood-2007-02-074997].
  • 5Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, BertoniA, Frassoni F, Bartolomé ST, Sambuceti G, Traggiai E, Uccelli A.Mesenchymal stem cells impair in vivo T-cell priming by dendriticcells. Proc Natl Acad Sci USA 2011; 108: 17384-17389 [PMID:21960443 DOI: 10.1073/pnas.1103650108].
  • 6O'Donoghue K, Choolani M, Chan J, de la Fuente J, Kumar S,Campagnoli C, Bennett PR, Roberts IA, Fisk NM. Identification offetal mesenchymal stem cells in maternal blood: implications fornon-invasive prenatal diagnosis. Mol Hum Reprod 2003; 9: 497-502[PMID: 12837927 DOI: 10.1093/molehr/gag063].
  • 7Weng SL, Chang SJ, Cheng YC, Wang HY, Wang TY, Chang MD,Wang HW. Comparative transcriptome analysis reveals a fetal originfor mesenchymal stem cells and novel fetal surface antigens fornoninvasive prenatal diagnosis. Taiwan J Obstet Gynecol 2011; 50:447-457 [PMID: 22212316 DOI: 10.1016/j.tjog.2011.10.009].
  • 8Pennington EC, Gray FL, Ahmed A, Zurakowski D, Fauza DO.Targeted quantitative amniotic cell profiling: a potential diagnostictool in the prenatal management of neural tube defects. J PediatrSurg 2013; 48: 1205-1210 [PMID: 23845608 DOI: 10.1016/j.jpedsurg.2013.03.009].
  • 9Ramírez M, Lucia A, Gómez-Gallego F, Esteve-Lanao J, Pérez-Martínez A, Foster C, Andreu AL, Martin MA, Madero L, ArenasJ, García-Castro J. Mobilisation of mesenchymal cells into bloodin response to skeletal muscle injury. Br J Sports Med 2006; 40:719-722 [PMID: 16807304 DOI: 10.1136/bjsm.2006.028639].
  • 10Dalle Carbonare L, Valenti MT, Zanatta M, Donatelli L, Lo CascioV. Circulating mesenchymal stem cells with abnormal osteogenicdifferentiation in patients with osteoporosis. Arthritis Rheum 2009;60: 3356-3365 [PMID: 19877060 DOI: 10.1002/art.24884].

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部